MEMPHASYS LIMITED. — Capital/Financing Update 2017

Nov 21, 2017

ASX Release

==> picture [222 x 64] intentionally omitted <==

(ASX: MEM)

Sydney, Wednesday 22 November 2017

Share issue price for Capital raising to accelerate development of Felix device

The Directors of Memphasys Limited (ASX: MEM) advise that pursuant to the $3.75M capital raising announcement issued to the market on 21 November 2017, the shares issued pursuant to the capital raising will be issued at a price of $0.001 per Share. The issue of shares will be subject to shareholder approval at a General Meeting of Shareholders to be held on Thursday 21 December 2017.

The proposed $3.75M of funds raised under the Capital Raising, together with the conversion of debt, will see Memphasys significantly strengthen its balance sheet at a time when the Company is focused on the development of the Company’s first commercial product, “Felix”, to treat male infertility. This product is based on innovative separation techniques using the Company's proprietary membrane technology.

For further information please contact:

Alison Coutts Executive Chairman +61 2 8415 7300 alison.coutts@memphasys.com

About Memphasys:

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Postal Address Contact Details E info@memphasys.com P.O. Box 2202 P +612 8415 7300 W memphasys.com Homebush West NSW 2140 F +612 8415 7399 ABN 33 120 047 556

Memphasys Limited 30-32 Richmond Road Homebush West NSW 2140

DM3\4802566.1